Personalized Medicine · 2019 · 10 citations · 30 references
MedicineGeneticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsDrug Metabolism GeneticsHepatic Drug MetabolismHepatic ToxicityHepatotoxicity MechanismsPharmacogenetic TestingControl Group DesignCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2c19 PharmacogeneticsCytochrome P450 2C19 GenotypingCytochrome P450 Genetic PolymorphismCytochrome P450 GenotypingMatched Control Group
Aim: This study investigated the association between voriconazole-induced liver injury and gene polymorphisms of CYP2C19 and UGT1A4. Materials & methods: Thirty-eight adult patients who received voriconazole therapy were included in the study. Genotype of CYP2C19 was detected using gene chip hybrid analysis. The UGT1A4 142T>G was genotyped using PCR-RFLP analysis. Results: Ten patients (26.3%) had voriconazole-induced liver injury and were considered as the case group There was no significant difference between the two groups in genotype and allele frequencies of CYP2C19*2 and UGT1A4 142T>G (p > 0.05), however, the GA frequency of CYP2C19 *3 in the drug-induced liver injury case group was higher than that in the control group (p < 0.05). Compared with patients carrying *1/*1 or *1/*2, there was no significant difference in voriconazole trough concentration of the patients with *1/*3 (p > 0.05). Conclusion: There was no significant correlation between voriconazole-induced liver injury and gene polymorphisms of CYP2C19 and UGT1A4.
30
Thomas F. Patterson, George R. Thompson, David W. Denning et al. · Clinical Infectious Diseases · 2016 · 2.8K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +17